Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 12, 2026 16:05 ET | Source: Rezolute, Inc.

Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all...
February 04, 2026 07:00 ET | Source: Rezolute, Inc.

Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all...
January 07, 2026 07:00 ET | Source: Rezolute, Inc.

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indicationsCompany plans to meet with FDA to align on path forward for...
December 11, 2025 07:00 ET | Source: Rezolute, Inc.

Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Study did not meet the primary or key secondary endpoint 45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host...
November 10, 2025 17:30 ET | Source: Rezolute, Inc.

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by...
November 06, 2025 16:05 ET | Source: Rezolute, Inc.

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by...
November 05, 2025 07:30 ET | Source: Rezolute, Inc.

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

REDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by...
October 15, 2025 08:00 ET | Source: Rezolute, Inc.

Rezolute to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by...
October 09, 2025 16:05 ET | Source: Rezolute, Inc.

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by...
September 17, 2025 16:05 ET | Source: Rezolute, Inc.

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by...